December 31, 2021
Susan M. O’Brien, MD, on potential upcoming approvals in 2022 for treating chronic lymphocytic leukemia with combination therapies.
December 30, 2021
Susan M. O’Brien, MD, on upcoming 2022 trends in chronic lymphocytic leukemia treatment.
December 29, 2021
Susan M. O’Brien, MD, on why clinical trial enrollment is so important for patients with chronic lymphocytic leukemia.
December 27, 2021
Susan M. O’Brien, MD, highlights ongoing trials from 2021 examining combination therapies for patients with chronic lymphocytic leukemia.
December 24, 2021
Susan M. O’Brien, MD, discusses novel mechanisms of action and BTK inhibitors for patients with chronic lymphocytic leukemia.
December 23, 2021
Susan M. O’Brien, MD, on common toxicities and adverse effects when treating patients with chronic lymphocytic leukemia.
December 21, 2021
Susan M. O’Brien, MD, on combination therapies for treating patients with chronic lymphocytic leukemia.
December 19, 2021
Susan M. O’Brien, MD, on treating patients with 17p deletions and TP53 mutations who have chronic lymphocytic leukemia.
December 17, 2021
Susan M. O’Brien, MD, on the approved BTK inhibitors for treating chronic lymphocytic leukemia.
December 15, 2021
Susan M. O’Brien, MD, discussed the emergence of noncovalent BTK inhibitors for treating chronic lymphocytic leukemia.